JP2018030807A - ペプチド - Google Patents
ペプチド Download PDFInfo
- Publication number
- JP2018030807A JP2018030807A JP2016163465A JP2016163465A JP2018030807A JP 2018030807 A JP2018030807 A JP 2018030807A JP 2016163465 A JP2016163465 A JP 2016163465A JP 2016163465 A JP2016163465 A JP 2016163465A JP 2018030807 A JP2018030807 A JP 2018030807A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- present
- inflammatory bowel
- bowel disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 39
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 23
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 101150109862 WNT-5A gene Proteins 0.000 description 4
- 102000043366 Wnt-5a Human genes 0.000 description 4
- 108700020483 Wnt-5a Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 101100264057 Mus musculus Wnt5a gene Proteins 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
項1. 下記のアミノ酸配列(I)
QLADFRKVGDALKEKYDSAAAMR (I)
を含む、ペプチド。
項2. 下記のアミノ酸配列(Ia)
R1−QLADFRKVGDALKEKYDSAAAMR (Ia)
(式中、R1は下記の13種
GVSGSCSLKTCWL、
VSGSCSLKTCWL、
SGSCSLKTCWL、
GSCSLKTCWL、
SCSLKTCWL、
CSLKTCWL、
SLKTCWL、
LKTCWL、
KTCWL、
TCWL、
CWL、
WL、又は
L
のいずれかである)
を含む、項1に記載のペプチド。
項3. GVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRで表される、項1又は2に記載のペプチド
項4. 項1,2又は3のペプチドを有効成分として含む炎症性腸疾患の予防又は治療剤。
項5. 項1,2又は3のペプチドを有効成分として含む大腸がん治療剤。
配列番号1: QLADFRKVGDALKEKYDSAAAMR
配列番号2: GVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMR
ヒト及びマウスのWnt5aの塩基配列及びアミノ酸配列は公知であり、データベースに下記のアクセッション番号で登録されている。
マウスのWnt5a : NM_009524
ヒトのWnt5a : NM_003392
ヒトとマウスのWnt5aの配列番号1,2に対応するアミノ酸配列は同一であり、本発明のペプチドは、ヒト及びマウスを含む哺乳動物に対し、炎症性腸疾患の予防又は治療剤、並びに、大腸がん治療剤として有用である。
配列番号2:GVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMR
6週齢BALB-Cマウスの背側に培養したColon26(マウス大腸癌細胞株)を皮下移植(皮下注)し、同日より投与を開始した。PBS(200μl)連日腹腔内投与群をコントロール群、PBSに溶解した36アミノ酸の配列番号1のWnt5a ペプチド(20μg/200μl)の連日腹腔内投与群を治療群とした(各群5匹)。その後経時的に両群の腫瘍径を測定し、比較検討した。結果を図1に示す。
YAMC細胞(Young Adult Mouse Colonic epithelial cell)におけるwound healing assay(YAMC細胞を用いたwound healing assayに関する参考論文:Uchiyama K, et al., BBRC 391(2010) 1122-1126)において、配列番号1の36アミノ酸のペプチドの濃度が10ng/mlでYAMC細胞の創傷治癒を亢進した。
Claims (5)
- 下記のアミノ酸配列(I)
QLADFRKVGDALKEKYDSAAAMR (I)
を含む、ペプチド。 - 下記のアミノ酸配列(Ia)
R1−QLADFRKVGDALKEKYDSAAAMR (Ia)
(式中、R1は下記の13種
GVSGSCSLKTCWL、
VSGSCSLKTCWL、
SGSCSLKTCWL、
GSCSLKTCWL、
SCSLKTCWL、
CSLKTCWL、
SLKTCWL、
LKTCWL、
KTCWL、
TCWL、
CWL、
WL、又は
L
のいずれかである)
を含む、請求項1に記載のペプチド。 - GVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRで表される、請求項1又は2に記載のペプチド
- 請求項1,2又は3のペプチドを有効成分として含む炎症性腸疾患の予防又は治療剤。
- 請求項1,2又は3のペプチドを有効成分として含む大腸がん治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016163465A JP6841404B2 (ja) | 2016-08-24 | 2016-08-24 | ペプチド |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016163465A JP6841404B2 (ja) | 2016-08-24 | 2016-08-24 | ペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018030807A true JP2018030807A (ja) | 2018-03-01 |
JP6841404B2 JP6841404B2 (ja) | 2021-03-10 |
Family
ID=61304575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016163465A Active JP6841404B2 (ja) | 2016-08-24 | 2016-08-24 | ペプチド |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6841404B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020196651A1 (ja) * | 2019-03-28 | 2020-10-01 | 国立大学法人東北大学 | がんの予防又は治療剤 |
-
2016
- 2016-08-24 JP JP2016163465A patent/JP6841404B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020196651A1 (ja) * | 2019-03-28 | 2020-10-01 | 国立大学法人東北大学 | がんの予防又は治療剤 |
Also Published As
Publication number | Publication date |
---|---|
JP6841404B2 (ja) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | NOD-like receptors in infection, immunity, and diseases | |
Pashenkov et al. | NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases | |
EA023886B1 (ru) | Селективные аналоги глюкагонподобного пептида-2 (glp-2) | |
US10293025B2 (en) | Oral administration compositions comprising an OB-fold protein variant | |
JP5052338B2 (ja) | 癌治療薬 | |
JP2010529026A5 (ja) | ||
US20230090435A1 (en) | Compounds with Antimicrobial Properties | |
WO2013004069A1 (zh) | 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 | |
JP6841404B2 (ja) | ペプチド | |
US9303066B2 (en) | Treatments for gastrointestinal disorders | |
WO2017014604A1 (en) | Novel peptide and use thereof | |
JP2006502193A5 (ja) | ||
WO2021096479A1 (en) | Treatment for inflammatory bowel disease and radiation-induced intestinal injury | |
JP5597534B2 (ja) | 抗腫瘍性の薬物、医薬、組成物、およびその使用 | |
US9790186B2 (en) | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | |
JP2014531442A5 (ja) | ||
CN112674028B (zh) | 促诱癌剂诱发动物癌症模型建立的方法 | |
CN111574590B (zh) | 一种具有抗肿瘤功能的多肽及其应用 | |
刘晨喆 | The Mechanism Underlying the Protective Effect of Rasagiline on Colonic Motility of 6-OHDA Rats | |
JP2014198711A (ja) | Ct阻害4価ペプチドおよびコレラ治療薬 | |
JP2009007255A (ja) | 肺がん治療薬 | |
Van De Bunt et al. | P070 Novel long-acting lipidated interleukin-22 normalises colonic inflammation in an acute DSS colitis model | |
CN110885361A (zh) | 一种口服抗肿瘤疫苗及其使用方法 | |
JP2016027018A (ja) | Lt阻害4価ペプチドおよびetec感染症治療薬 | |
JPWO2005042007A1 (ja) | 抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20161104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200728 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200915 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6841404 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |